Meet the ProBio consortium: healthcare professionals from 🇸🇪🇧🇪🇳🇴🇨🇭specialised in the treatment of men with metastatic #ProstateCancer They made the 🥈#ProBioTrial International Investigator’s Meeting a success 🙏 Presentations soon available on probiotrial.org

Don’t forget the ProBio is an investigator-initiated trial! Crazy level of commitment of everyone involved.

Secondly, my (co)promotors Piet Ost and Katleen De Preter for giving me the opportunity 5 years ago to start. Bram De Laere not only for being my boss and scientific mentor but for being a life-long friend that I hold dear.

The very talented Dr Jan Vanwelkenhuyzen about to embark on a new journey in his academic career. It has been a privilege to mentor you the past 8 years and advance #ProstateCancer research!

Ian Davis (Bluesky @profiand) Declan Murphy Neeraj Agarwal, MD, FASCO OncoAlert PCF Science UroToday.com GU CONNECT Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Umang Swami, MD, MSCI, FASCO Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) GU Cancer Research Program @HuntsmanCancer Arun Azad Andrea Apolo, M.D. Shilpa Gupta Petros Grivas silke gillessen That makes zero sense. And a quote from Edison makes it right. Doing 10.000 trials will induce a ton of financial harm, toxicity and delay the development of other strategies. 'FIRST, DO NO HARM'. Thomas Sydenham.

A privilege to discuss our 🩸🧬 biomarker-driven ProBio together with Zach Klaassen Thank you UroToday.com for the invitation 🙏🏻 ➡️Visit probiotrial.org or ProBio for more info!

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. Bram De Laere UGent joins Zach Klaassen Georgia Cancer Center to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo

Important work from the ProBio team! Proud to be a contributor. #probio #prostatecancer Bram De Laere Piet Ost Renée Bultijnck eur03.safelinks.protection.outlook.com/?url=https%3A%…

🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]

🏅Key result: 🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had ➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB) ➡️a 51% longer overall survival (OS) 📉 #CancerBiomarkers [4/8]

🏅Secondary result: We found a linear relationship between ctDNA 🩸 levels and outcome: 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome! #PrecisionMedicine [5/8]

Proud to share the latest insights from the ProBio Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant #ProstateCancer 🩸🧬 Full text available on European Urology Oncology : authors.elsevier.com/sd/article/S25…

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

Goutham Sunny Daniel E Spratt But if you ask the companies Merck to provide drug for a biomarker selection trial like ProBio, they refuse. Even if you ask for compassionate use for PCa MSI high in the trial!!! Bram De Laere

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across